Source: International Congress 2019 – New Horizons in The Treatment of Pulmonary Fibrosis
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
P. Sime (Rochester, United States of America). The pathogenesis of IPF: what is the latest paradigm?. International Congress 2019 – New Horizons in The Treatment of Pulmonary Fibrosis

Member's Comments

No comment yet.

Related content which might interest you: The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF Source: Eur Respir J 2015; 46: 883-886 Year: 2015 IPF: a distinct clinical entity? Source: International Congress 2017 – State of the art session: "Interstitial lung disease and pulmonary vascular diseases" Year: 2017 Z-alpha1-antitrypsin polymers and small airways disease: a new paradigm in COPD development? Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 Making the case for causality: what role do lung microbiota play in idiopathic pulmonary fibrosis? Source: Eur Respir J, 55 (4) 2000318; 10.1183/13993003.00318-2020 Year: 2020 The current classification of the idiopathic interstitial pneumonias: has it advanced pathogenetic understanding Source: Research Seminar 2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar Year: 2010 Are genetic defects of dienin a key link in the pathogenesis of COPD? Source: Virtual Congress 2020 – Physiological and cellular mechanisms affecting pulmonary pathologies Year: 2020 Late Breaking Abstract: An animal model for studies on pathogenesis and pharmaceutical intervention of chronic asthma Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 What have we learned from basic science studies on idiopathic pulmonary fibrosis? Source: Eur Respir Rev, 28 (153) 190029; 10.1183/16000617.0029-2019 Year: 2019 Idiopathic pulmonary fibrosis (IPF): epidemiology, biology, diagnosis and treatment Source: Virtual Congress 2020 – When the lung gets stiff Year: 2020 Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression? Source: Eur Respir J , 49 (2) 1602345; DOI: 10.1183/13993003.02345-2016 Year: 2017 Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression? Source: Eur Respir J , 49 (2) 1602524; DOI: 10.1183/13993003.02524-2016 Year: 2017 Idiopathic pulmonary fibrosis: present understanding and future options Source: Eur Respir Rev 2011; 20: 132-133 Year: 2011 CF: pathogenesis treatment strategies Source: International Congress 2018 – Russian Speaking Programme 2018: Part I Year: 2018 Omics in population studies: a molecular epidemiology perspective in chronic airway disease Source: International Congress 2014 – Personalised exposure and gene environment interactions in chronic airway disease: the exposome and epigenome Year: 2014 Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance? Source: Eur Respir J, 55 (6) 2000811; 10.1183/13993003.00811-2020 Year: 2020 SSc-ILD: are we entering a new chapter in treatment? Source: International Congress 2019 – New Horizons in The Treatment of Pulmonary Fibrosis Year: 2019 What is the reason for comorbidities in COPD: pathophysiology? Source: Annual Congress 2012 - When the whole body is affected: comorbodity and COPD Year: 2012